Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.

SZSE:301093 Stock Report

Market Cap: CN¥2.9b

Jiangsu Hualan New Pharmaceutical MaterialLtd Future Growth

Future criteria checks 5/6

Jiangsu Hualan New Pharmaceutical MaterialLtd is forecast to grow earnings and revenue by 43.1% and 28% per annum respectively. EPS is expected to grow by 41% per annum. Return on equity is forecast to be 7.5% in 3 years.

Key information

43.1%

Earnings growth rate

41.0%

EPS growth rate

Medical Equipment earnings growth26.3%
Revenue growth rate28.0%
Future return on equity7.5%
Analyst coverage

Low

Last updated07 Sep 2024

Recent future growth updates

Recent updates

Weak Statutory Earnings May Not Tell The Whole Story For Jiangsu Hualan New Pharmaceutical MaterialLtd (SZSE:301093)

Sep 03
Weak Statutory Earnings May Not Tell The Whole Story For Jiangsu Hualan New Pharmaceutical MaterialLtd (SZSE:301093)

Is Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. (SZSE:301093) Trading At A 36% Discount?

Jun 07
Is Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. (SZSE:301093) Trading At A 36% Discount?

Earnings and Revenue Growth Forecasts

SZSE:301093 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,158248N/A2431
12/31/2025898176N/A1911
12/31/2024722129N/A1671
9/30/20245928114215N/A
6/30/2024604953263N/A
3/31/202459395-6252N/A
12/31/2023623118-73224N/A
9/30/2023631106-124160N/A
6/30/202361998-118133N/A
3/31/202361096-129109N/A
1/1/202358494-7995N/A
9/30/202258610845178N/A
6/30/202269116490207N/A
3/31/2022784206114243N/A
1/1/202282121693217N/A
9/30/202178421466150N/A
6/30/202163315152116N/A
3/31/202150910361102N/A
12/31/20204468194133N/A
12/31/2019460955686N/A
12/31/20184348687107N/A
12/31/201738877N/A34N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 301093's forecast earnings growth (43.1% per year) is above the savings rate (2.8%).

Earnings vs Market: 301093's earnings (43.1% per year) are forecast to grow faster than the CN market (26.1% per year).

High Growth Earnings: 301093's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 301093's revenue (28% per year) is forecast to grow faster than the CN market (13.8% per year).

High Growth Revenue: 301093's revenue (28% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 301093's Return on Equity is forecast to be low in 3 years time (7.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y